Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
Day's Change
1.45 (4.56%)
B/A Size
Day's High
Day's Low

10-day average volume:

Digital World stock surges after Elon Musk terminates Twitter purchase

6:15 pm ET July 8, 2022 (MarketWatch)

Shares of Digital World Acquisition Corp. (DWAC) were rocketing 17% in after-hours trading Friday after Tesla Inc. (TSLA) Chief Executive Elon Musk said he was terminating his $44 billion deal for Twitter Inc. (TWTR). Digital World is a special-purpose acquisition corporation buying the company that operates President Donald Trump's Truth Social business, which bills itself as a social network that "encourages an open, free, and honest global conversation without discriminating on the basis of political ideology." Trump was banned from Twitter in the wake of Jan. 6, 2021, but Musk had signaled after initially agreeing to buy the company that he would look to reverse that ban and that he more generally disagreed with permanent bans. He had also indicated that he would take a less strict approach to content moderation. DWAC's aftermarket rally Friday suggests that investors see Twitter as less threatening to Truth Social as a public company not controlled by Musk. DWAC shares have lost 47% over the past three months, as Twitter shares have dropped 20% and as the S&P 500 has fallen 13%.

-Emily Bary


(END) Dow Jones Newswires

July 08, 2022 18:15 ET (22:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.